A 45-year-old woman presents with irregular vaginal bleeding and an enlarged uterus. A biopsy reveals endometrial hyperplasia with atypia. What is the next best step in management?
A 36-year-old woman with a history of endometriosis presents with chronic pelvic pain and infertility. What is the best initial management?
A 34-year-old female presents with chronic pelvic pain and infertility. Laparoscopy reveals adhesions between the uterus and surrounding structures. Which condition is most likely responsible for these findings?
A 40-year-old woman is diagnosed with endometriosis. Which location is most commonly affected by this condition?
In diagnosing endometriosis, which symptom is most specifically associated with deep infiltrating endometriosis and serves as an important diagnostic clue?
A gynecologist is treating a patient with a molar pregnancy. What is the most appropriate next step in management?
A 36-year-old woman presents with intermenstrual bleeding and a palpable mass in the pelvis. Which imaging study is most appropriate to evaluate for a leiomyoma?
Which procedure is indicated for a 45-year-old woman with symptomatic uterine fibroids who desires future fertility?
In a postmenopausal woman with vaginal bleeding, what is the first-line investigation to rule out endometrial cancer?
A 29-year-old woman with a history of fibroids presents with menorrhagia. Which medication is most appropriate for managing her symptoms?
Explanation: ***Hysterectomy*** - Endometrial hyperplasia with **atypia** carries a significant risk of progression to **endometrial cancer** (up to 30%), especially in a 45-year-old woman presenting with irregular bleeding. - Given the risk of malignancy and the patient's age (likely completed childbearing), **hysterectomy** is considered the definitive treatment and the next best step for preventing cancer. *Hormonal therapy* - While hormonal therapy (e.g., progestins) can be used for **endometrial hyperplasia without atypia**, or in younger women who wish to preserve fertility, it is less appropriate for hyperplasia with atypia due to the high risk of cancer. - This option would typically be considered if the patient was younger, desired fertility, or had significant contraindications to surgery, and would require close monitoring. *Uterine ablation* - **Uterine ablation** is a procedure to destroy the uterine lining and is primarily used to treat **heavy menstrual bleeding that is not caused by cancer**. - It does not remove the entire uterus and, therefore, is not an appropriate treatment for **atypical endometrial hyperplasia** which has a high malignant potential, as it could mask or prevent further evaluation of precancerous or cancerous changes. *Watchful waiting* - **Watchful waiting** is inappropriate for endometrial hyperplasia with atypia due to the significant risk of progression to **endometrial cancer**. - Delaying definitive treatment can lead to more advanced disease, making outcomes worse.
Explanation: ***Surgical resection*** - For women with **moderate-to-severe endometriosis** (Stage III-IV) presenting with infertility and chronic pelvic pain, surgical resection of endometriotic implants is often the **best initial management**. - Surgery aims to **reduce disease burden**, restore normal pelvic anatomy, and remove endometriomas, which can **improve spontaneous conception rates** and alleviate pain. - **Laparoscopic excision** is preferred, as it provides both diagnostic confirmation and therapeutic benefit, with studies showing improved pregnancy rates post-operatively in appropriately selected patients. - This approach is particularly beneficial when there are **visible lesions, adhesions, or ovarian endometriomas** affecting fertility. *NSAIDs* - **NSAIDs** provide **symptomatic pain relief** but do not address the underlying endometriosis or improve fertility outcomes. - While useful as adjunctive therapy, they are insufficient as sole initial management for patients seeking conception. *GnRH agonists* - **GnRH agonists** induce a **hypoestrogenic state** that reduces endometriotic lesions and pain by suppressing ovarian function. - However, they cause **temporary anovulation**, making them unsuitable for women actively trying to conceive. - They may be used preoperatively to reduce lesion size or postoperatively to prevent recurrence, but not as initial management for infertility. *IVF* - **In vitro fertilization (IVF)** is an effective option for endometriosis-related infertility, particularly in **minimal-to-mild disease** or after failed surgical management. - While IVF bypasses tubal and peritoneal factors, it does **not treat the underlying endometriosis** or alleviate chronic pelvic pain. - In cases with significant anatomical distortion or endometriomas, **surgical management is typically preferred initially** to optimize pelvic environment before considering assisted reproductive technology.
Explanation: ***Correct: Endometriosis*** - **Endometriosis** is a chronic condition where endometrial-like tissue grows outside the uterus, leading to **chronic pelvic pain, dysmenorrhea, and infertility** - These ectopic endometrial implants cause **chronic inflammation** and **adhesion formation** between pelvic structures, which are characteristic laparoscopic findings - The classic triad of endometriosis includes: chronic pelvic pain, infertility, and dysmenorrhea - Laparoscopy is the **gold standard** for diagnosis, revealing endometrial implants, adhesions, and "powder-burn" lesions *Incorrect: Pelvic inflammatory disease (PID)* - PID is an infection of the upper female genital tract, typically caused by sexually transmitted organisms like *Chlamydia trachomatis* or *Neisseria gonorrhoeae* - While PID can cause adhesions (particularly tubo-ovarian adhesions) and infertility, it presents primarily with **acute symptoms**: fever, purulent vaginal discharge, cervical motion tenderness - Chronic PID may cause adhesions, but the **acute/subacute infectious presentation** is the key distinguishing feature from the chronic presentation described *Incorrect: Uterine fibroids* - Uterine fibroids (leiomyomas) are benign smooth muscle tumors of the uterine wall - They typically cause **heavy menstrual bleeding (menorrhagia)**, pelvic pressure/bulk symptoms, and occasionally submucous fibroids can affect fertility - Fibroids **do not typically cause widespread pelvic adhesions** or the pattern of chronic pain described here - Laparoscopy would show enlarged uterus with masses, not adhesions between structures *Incorrect: Ovarian cysts* - Ovarian cysts are fluid-filled sacs that are commonly found and often asymptomatic - Simple functional cysts rarely cause chronic symptoms; complex cysts or endometriomas might cause localized pain - Cysts typically present with **acute pain if ruptured or torsed**, not chronic pelvic pain - While dermoid cysts or endometriomas can occasionally cause local adhesions, they would not explain the **widespread adhesions and infertility** pattern described without being part of endometriosis itself
Explanation: ***Ovaries*** - The **ovaries** are the **most common site** for endometriosis, with ovarian involvement occurring in **50-70% of cases**. - Endometriosis commonly presents as **endometriomas** (chocolate cysts) in the ovaries. - This high frequency is due to the proximity to peritoneal fluid and ease of implantation of refluxed endometrial cells. *Fallopian tubes* - While endometriosis can affect the fallopian tubes, it is **less common** than ovarian involvement. - Tubal endometriosis may contribute to **infertility** through obstruction or altered tubal function. - Can rarely lead to increased risk of **ectopic pregnancy**. *Uterine cervix* - Cervical endometriosis is **rare**, accounting for a very small percentage of cases. - The cervix is lined by different epithelium, making it less hospitable for endometrial tissue implantation. *Peritoneum* - The pelvic peritoneum is frequently involved in endometriosis, with superficial implants commonly seen. - However, the **ovaries** remain the **single most commonly affected organ** when considering organ-specific involvement. - Peritoneal implants typically present as superficial lesions contributing to **pelvic pain** and adhesions.
Explanation: ***Dyspareunia*** - **Dyspareunia** (painful intercourse, particularly deep dyspareunia) is a highly characteristic symptom of endometriosis, especially when endometrial implants are located on the **uterosacral ligaments**, in the **pouch of Douglas**, or involve **deep infiltrating endometriosis**. - Deep dyspareunia has good specificity for endometriosis and provides an important diagnostic clue regarding the anatomical location of lesions. - **Important note**: While dyspareunia is diagnostically significant, symptom severity does NOT correlate well with disease stage—women with minimal disease can have severe symptoms. *Intermittent pelvic discomfort* - While **chronic pelvic pain** is common in endometriosis, "intermittent pelvic discomfort" is a very general term that can be associated with many gynecological, gastrointestinal, or urological conditions. - It lacks the specificity of deep dyspareunia in indicating endometriosis, particularly deep infiltrating disease. - **Note**: Cyclic dysmenorrhea (painful periods) would be more characteristic than intermittent discomfort. *Chronic tiredness* - **Chronic fatigue** can be a secondary symptom experienced by women with endometriosis due to chronic pain, inflammation, and sleep disturbances. - However, it is a non-specific symptom that does not directly point to endometriosis and provides limited diagnostic value. *Irregular menses* - **Irregular menses** can be associated with various hormonal imbalances, stress, PCOS, or other reproductive conditions, and is NOT a primary or characteristic symptom of endometriosis. - Women with endometriosis typically have regular cycles but experience **dysmenorrhea** (painful periods), which is the most common symptom of endometriosis (present in 50-90% of cases). - The presence of irregular bleeding should prompt evaluation for other conditions rather than primarily suggesting endometriosis.
Explanation: ***Uterine evacuation*** - The primary treatment for a **molar pregnancy** is **uterine evacuation**, typically performed via **suction curettage**. - This procedure removes the abnormal trophoblastic tissue to prevent complications such as persistent trophoblastic disease or choriocarcinoma. *Expectant management* - **Expectant management** is generally unsuitable for molar pregnancy due to the high risk of severe hemorrhage, infection, and malignant transformation. - Delaying evacuation can significantly increase the chances of developing **gestational trophoblastic neoplasia (GTN)**. *Methotrexate therapy* - **Methotrexate** is used to treat **gestational trophoblastic neoplasia (GTN)**, which is a complication that can arise *after* molar pregnancy. - It is not the initial treatment for the evacuation of the molar pregnancy itself. *Hysterectomy* - **Hysterectomy** is a definitive treatment that may be considered in cases of intractable bleeding, very large or recurrent molar pregnancies, or as a treatment for **high-risk gestational trophoblastic neoplasia**, especially in older patients who have completed childbearing. - However, for initial management of a molar pregnancy, it is generally an *over-aggressive* approach for most patients who wish to preserve fertility.
Explanation: ***Transvaginal ultrasound*** - This is typically the **first-line imaging modality** for evaluating uterine and pelvic pathology, including **leiomyomas**, due to its high resolution, non-invasiveness, and availability. - It effectively visualizes the **uterus, ovaries, and surrounding structures**, allowing for the detection of the size, number, and location of fibroids. *CT scan of the abdomen and pelvis* - While it can identify large leiomyomas, CT involves **ionizing radiation** and is generally less sensitive than ultrasound or MRI for detailed soft tissue pelvic imaging. - It is often reserved for evaluating **malignancy** or when there is suspicion of extension beyond the pelvic cavity. *MRI of the pelvis* - MRI provides **excellent soft tissue contrast** and can be very useful for differentiating between various pelvic masses, especially for surgical planning or when ultrasound findings are inconclusive. - However, it is **more expensive** and less readily available than ultrasound, often used as a **second-line investigation**. *X-ray pelvis* - An X-ray has **limited utility** for evaluating soft tissue structures like leiomyomas, as it primarily visualizes bones. - It would not provide sufficient detail to diagnose or characterize a **uterine fibroid**.
Explanation: ***Myomectomy*** - **Myomectomy** is the procedure of choice for women with symptomatic uterine fibroids who wish to preserve their **fertility** - It involves the surgical removal of the fibroids while leaving the **uterus intact**, allowing for future pregnancies - This is the standard fertility-sparing surgical option recommended by ACOG guidelines *Incorrect: Hysterectomy* - **Hysterectomy** involves the surgical removal of the uterus, which immediately and permanently eliminates any possibility of future **fertility** - It is typically reserved for women who no longer desire children or for cases where fibroids are extensive and other fertility-sparing options are not viable *Incorrect: Endometrial ablation* - **Endometrial ablation** destroys the lining of the uterus to reduce heavy menstrual bleeding, making subsequent pregnancy highly **risky and inadvisable** - While it does not remove fibroids (used for menorrhagia, not fibroids), it permanently impairs the ability to safely carry a pregnancy to term - This is not a treatment for uterine fibroids *Incorrect: Uterine artery embolization* - **Uterine artery embolization (UAE)** involves blocking the blood supply to fibroids, causing them to shrink - Although less invasive, its impact on future fertility and pregnancy outcomes is **variable and carries higher risks** compared to myomectomy - The effects of UAE on the uterine blood supply and endometrial health can make successful pregnancy and delivery more challenging - Generally not recommended as first-line for women desiring future fertility
Explanation: ***Transvaginal ultrasound*** - **Transvaginal ultrasound (TVUS)** is the recommended first-line investigation in postmenopausal women with vaginal bleeding to assess the **endometrial thickness**. - An **endometrial thickness of <4 mm** on TVUS generally rules out endometrial cancer with high confidence, while a thicker endometrium warrants further investigation. *Endometrial biopsy* - While an **endometrial biopsy** is the gold standard for diagnosing endometrial cancer, it is typically performed *after* an abnormal TVUS finding (e.g., endometrial stripe >4 mm) or if TVUS is inconclusive. - It is an **invasive procedure** and not the initial screening tool for all postmenopausal bleeding. *Hysteroscopy* - **Hysteroscopy** involves direct visualization of the uterine cavity and is often combined with targeted biopsy. It is usually performed if TVUS or blind endometrial biopsy is inconclusive or to evaluate focal lesions. - It is a **more invasive** and resource-intensive procedure, not suitable as a first-line screening tool. *Pap smear* - A **Pap smear** screens for **cervical cellular abnormalities** and cervical cancer, not endometrial cancer. - It is **not effective** in detecting endometrial pathology, and a normal result does not rule out endometrial cancer in a woman with postmenopausal bleeding.
Explanation: ***Progesterone IUD*** - A **progesterone IUD (e.g., Mirena)** is highly effective for managing menorrhagia associated with fibroids by causing **endometrial atrophy** and reduced blood loss. - It provides **localized hormone delivery**, minimizing systemic side effects, and is a long-acting reversible contraceptive. *Oral contraceptive pills* - While OCPs can reduce menstrual bleeding, their effectiveness in managing significant menorrhagia due to **fibroids** may be limited compared to other options. - They also carry risks like **thromboembolism**, which might be a consideration for some patients. *GnRH agonists* - **GnRH agonists (e.g., leuprolide)** induce a **hypoestrogenic state**, which can shrink fibroids and reduce bleeding, but their use is typically short-term due to side effects like hot flashes and bone loss. - They are often used as a pre-operative measure rather than a long-term solution for symptomatic management. *NSAIDs* - **NSAIDs (e.g., ibuprofen, naproxen)** primarily work by reducing **prostaglandin production**, which can decrease menstrual blood flow and pain. - However, they are generally less effective for **heavy bleeding** associated with significant fibroids compared to hormonal treatments.
Abnormal Uterine Bleeding
Practice Questions
Endometriosis
Practice Questions
Adenomyosis
Practice Questions
Uterine Fibroids
Practice Questions
Ovarian Cysts
Practice Questions
Pelvic Inflammatory Disease
Practice Questions
Vulvovaginitis
Practice Questions
Pelvic Organ Prolapse
Practice Questions
Vulvar Disorders
Practice Questions
Benign Breast Diseases
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free